Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History VERV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics VERV

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Verve Therapeutics Inc

VERV
Current price
10.91 USD -0.07 USD (-0.64%)
Last closed 11.02 USD
ISIN US92539P1012
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 984 220 480 USD
Yield for 12 month +58.35 %
1Y
3Y
5Y
10Y
15Y
VERV
21.11.2021 - 28.11.2021

Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts. Address: 201 Brookline Avenue, Boston, MA, United States, 02215

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.11 USD

P/E Ratio

Dividend Yield

Financials VERV

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures VERV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+32 332 000 USD

Last Year

+11 758 000 USD

Current Quarter

+32 976 000 USD

Last Quarter

+13 080 000 USD

Current Year

+32 332 000 USD

Last Year

+11 758 000 USD

Current Quarter

+32 976 000 USD

Last Quarter

+13 080 000 USD
EBITDA -201 615 008 USD
Operating Margin TTM -111.10 %
Price to Earnings
Return On Assets TTM -19.35 %
PEG Ratio
Return On Equity TTM -34.26 %
Wall Street Target Price 15.11 USD
Revenue TTM 59 613 000 USD
Book Value 5.33 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 479.00 %
Dividend Yield
Gross Profit TTM -150 816 000 USD
Earnings per share -2.11 USD
Diluted Eps TTM -2.11 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation VERV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 9.32
Price Sales TTM 16.51
Enterprise Value EBITDA -0.40
Price Book MRQ 2.08

Technical Indicators VERV

For 52 Weeks

2.86 USD 11.41 USD
50 Day MA 7.43 USD
Shares Short Prior Month 17 997 670
200 Day MA 6.27 USD
Short Ratio 5.92
Shares Short 9 890 152
Short Percent 23.86 %